EGFR and glioblastoma: Diffuse astrocytoma with TERT promoter mutations, EGFR amplification, and/or +7/-10 copy number variants in IDH wild type have biological behavior equivalent to glioblastoma (WHO grade 4), even though they exhibit histologically as WHO grade 2/3 (19); WHO grade 2/3 IDH-wild/H3-wild diffuse glioma with BRAF V600E mutation, FGFR1 variant, and/or MYB/MYBL1 variant are suggestive of biological indolence and have a better prognosis for patients (20).